secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0002036042-25-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna Therapeutics Q2 net loss $18.1M; positive Phase 1 data for NBD1 stabilizers
--------------------------------------------------------------------------------

- Net loss $18.1M in Q2 2025 vs $8.6M in Q2 2024; R&D expenses $15.4M.
- Cash and equivalents $337.3M as of June 30, 2025; funding expected into 2028.
- Positive Phase 1 data for SION-719 and SION-451: well tolerated, exceeded PK targets.
- Phase 2a trial of SION-719 as add-on to CF standard of care on track for H2 2025; topline data mid-2026.
- Phase 1 dual combination trial of SION-451 with galicaftor and SION-109 on track for H2 2025; data mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000203604225000044/0002036042-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000203604225000044/sion-20250811.htm
  HTML page:      https://secwatch.observer/filing/0002036042-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer